Life Healthcare Group Holdings Limited Overview
Life Healthcare is one of South Africa's three dominant private hospital operators, alongside Netcare and Mediclinic. Following its exits from Poland, the UK and Europe, and global radiopharmaceuticals between 2021 and 2025, it is now a pure-play Southern African healthcare services group.
Core assets: - 42 acute hospitals with 8 085 acute beds;
-
a growing complementary-services platform spanning mental health, acute rehabilitation, renal dialysis, oncology, diagnostic imaging, nuclear medicine and radiopharmaceutical production;
-
a smaller healthcare-services arm comprising government-contracted chronic care (Life Nkanyisa) and occupational health (Life Health Solutions).
Economics: - The group is highly dependent on private medical schemes; c. 64% of revenue comes from three funders.
- Its normalised EBITDA margin (c. 15–16%) is structurally below Netcare's (c. 18.6%).
Balance sheet: After returning roughly R13 billion in special dividends since 2024, the balance sheet is lightly geared (0.93x net debt to EBITDA at March 2026).
Investment debate: The investment case now rests on:
-
recovering occupancy;
-
delivering a R400 million cost-saving programme;
-
greenfield and brownfield growth such as Life Paarl Valley; and
-
optionality from up to US$400 million of LMI earn-outs.
Overhang: These are set against persistent regulatory risk from National Health Insurance (NHI).
What the company does. Life Healthcare owns and operates private healthcare facilities, overwhelmingly in South Africa. It also operates a hospital in Botswana and renal dialysis units in Namibia.
The group reports three operating segments plus a corporate segment [S3]:
Hospitals: acute hospitals and day facilities.
Complementary services: mental health, acute physical rehabilitation, renal dialysis, oncology and diagnostics (MRI, CT, PET-CT, SPECT and nuclear medicine).
Healthcare services: Life Nkanyisa (government-contracted long-term care) and Life Health Solutions (occupational health, wellness, emergency medical services and primary care).
International: now only a residual UK holding entity carrying the Piramal liability and LMI-related receivables.
Company's own description. In its FY2025 and H1-2026 reporting the group frames itself around three ideas [S3]:
-
being a leading provider of value-based care, delivered through innovative contracting and reimbursement models;
-
offering a diversified range of services, extending into diagnostics and adjacent lines of business;
-
being people-centred and patient-insight driven, supported by data and technology.
Its stated purpose is "Making life better" [S26]. Its strategy is branded "Grow, Drive, Optimise", aimed at increasing market share, revenue and returns (MRR) [S2].
Business model and revenue model. The business is essentially 100% service revenue; there is no material product, subscription or licensing income after the LMI disposal.
H1-2026 revenue disaggregation [S3]:
Timing of recognition: R9 263 million (74.6%) of H1-2026 revenue was recognised over time (patient stays) and R3 159 million (25.4%) at a point in time (pharmaceuticals, consumables and discrete procedures) [S3].
Price setting: Hospital revenue is driven by paid patient days (PPDs) multiplied by revenue per PPD. Revenue per PPD is set by annual tariff negotiations with medical schemes and by case mix.
-
FY2025: average tariff increase 5.1% plus a 0.7% case-mix benefit, giving +5.8% revenue per PPD [S2].
-
H1-2026: average tariff increase fell to 3.3% [S3].
Alternative reimbursement: Value-based contracts and integrated care products (ICPs), for example renal, provide bundled or alternative reimbursement [S2].
Funder networks: Funder and network channels (designated-service-provider networks) accounted for 35% of PPDs in FY2025 [S2].
Value chain position. Life sits at the provider tier of the private healthcare value chain:
Downstream: It sits between funders (medical schemes and administrators) and patients.
Upstream: It buys from pharmaceutical and consumable suppliers (FY2025 drugs and consumables were about a quarter of revenue; H1-2026 R3 337 million, or 26.9%) and employs nursing staff (employee costs R4 996 million, or 40.2% of H1-2026 revenue) [S3].
Specialists: Under South African practice restrictions, specialists are largely independent practitioners admitting to Life facilities rather than employees. This makes doctor recruitment and retention a core commercial lever, with c. 140 recruits targeted for FY2026 [S4].
Customer types and end-markets.
Insured private patients: the predominant customer group. In 2024 South African medical schemes covered c. 9.17 million beneficiaries [S25].
Government: provincial health departments contract Life Nkanyisa beds and some hospital services.
Corporates: mining and industrial employers buy on-site occupational health.
Cash-paying patients: a small segment.
End-markets: acute inpatient care, emergency care (655 745 emergency-unit visits in FY2025 [S2]), cardiac care, mental health, rehabilitation, renal replacement therapy, oncology, diagnostic imaging and nuclear medicine.
Independent characterisation. Analytically, Life is a mature, capital-intensive, regulated-price business with high operating leverage to occupancy. Each percentage point of occupancy moves margin meaningfully, which is why management targets c. 70%. Exposure to medical-scheme membership growth is limited because scheme membership has been flat at c. 15% of the population for years [S25].
Where growth comes from: Organic growth relies on tariff inflation, case-mix and modest volume gains. Incremental growth is coming from complementary services, which grew revenue 24.7% in FY2025 [S2], and from greenfield and brownfield capacity.
Why the 2023–2025 disposals matter: They converted a complex, internationally diversified group into a simpler but less diversified, rand-only franchise. The resulting cash was returned to shareholders rather than reinvested.
Strategy
Stated strategy themes (FY2025 results; FY2025 integrated report). The strategy is "Grow, Drive, Optimise", with the objective of delivering high-quality, cost-effective care while increasing market share, revenue and returns [S2].
Medium-term financial targets and guidance. Management has not published formal multi-year margin or return targets in the sources reviewed. Evolution of FY2026 guidance:
Sources: [S1][S2][S4]. The May 2026 cut to revenue and occupancy guidance was cited by analysts as the reason for the 5% share-price fall on results day [S20].
Products & Services
Pricing across the hospital and complementary portfolio is tariff-based. Tariffs are negotiated annually with medical schemes or set by contract with government and corporate clients. List prices are not publicly disclosed.
Hospitals segment
| Offering | Description and capabilities | Target customer | Year / status | Pricing model | Flagship / named examples |
|---|---|---|---|---|---|
| Acute hospital network | 42 facilities, 8 085 acute beds, 293 theatres; general ward, ICU and high-care. ICU occupancy 84.3% in FY2025; 46 ICU beds added over two years [S2] | Medical-scheme members; network/DSP patients | Ongoing; 89 acute beds planned for FY2026, revised to 87 [S1][S4] | Per-diem / fee-for-service tariffs; ward and theatre fees; pharmacy and consumables | Life Eugene Marais (Pretoria; 14 theatres, hybrid theatre, neuro-spinal rehab) [S31]; Life Mt Edgecombe; Life Rosepark; Life Peglerae; Life Bedford Gardens (144 beds) [S18] |
| Emergency units | 39 emergency units; 655 745 visits in FY2025 [S2] | Walk-in and ambulance patients; the main admissions channel | Life Peglerae emergency unit upgraded in FY2025 [S2] | Facility fee plus admission | Life Peglerae Hospital (Rustenburg) |
| Cardiac network | 17 cathlabs and 5 vascular labs across a 15-facility cardiac network [S2] | Cardiology / vascular patients | New cathlab at Life Mt Edgecombe and new vascular lab at Life Rosepark planned for FY2026 [S2] | Procedure-based tariffs | Life Mt Edgecombe (Durban); Life Rosepark (Bloemfontein) |
| Theatre and surgical services | 293 theatres; theatre minutes +2.2% in FY2025; medical/surgical revenue split 54/46 in FY2025 [S2] | Surgeons and specialists | Ongoing | Theatre-minute tariffs | — |
| Day facilities | 5 day facilities (89 beds, 15 theatres) [S2] | Low-acuity surgical cases moving out of hospital | Ongoing | Day-case tariffs; alternative reimbursement | — |
| New greenfield hospital | Life Paarl Valley Hospital: 140 beds in a lodge-style setting; includes the only cardiac cathlab in the area [S19] | Western Cape Winelands, which is growing and attracting affluent retirees | Under construction; opening FY2027 (H2 2027) [S4][S19] | Standard tariffs | Located between Paarl and Franschhoek (corner Fraaigelegen Road and R301) |
Complementary services segment
| Offering | Description and capabilities | Target customer | Year / status | Pricing model | Flagship / named examples |
|---|---|---|---|---|---|
| Mental health | 9 facilities, 607 beds. Occupancy 76.6% in FY2025 [S2][S5] | Psychiatric and addiction patients (medical-scheme PMB conditions) | Ongoing | Per-diem tariffs | Life Hunterscraig Private Hospital (Gqeberha) [S20] |
| Acute physical rehabilitation | 7 units, 287 beds; 24 beds added in FY2025 [S2] | Post-stroke, spinal, trauma and orthopaedic patients | 40 beds planned for FY2026, revised to 64 [S1][S4] | Per-diem tariffs | — |
| Renal dialysis (Life Renal Dialysis / Life Renal Care) | 74 facilities, 1 089 stations [S2]. Includes 41 ex-Fresenius South African units (acquired 1 Apr 2024) and Namibian units (FY2025) | End-stage kidney disease patients | Treatments +9.3% in H1-2026; positive normalised EBITDA in H1-2026 after prior losses [S3]. 20 renal stations planned for FY2026 [S2] | Per-session tariffs; renal integrated care product (ICP) bundles [S2] | Three stand-alone renal sites closed and one being sold in H1-2026 [S3] |
| Oncology | 5 facilities, 32 chemotherapy units, 6 linear accelerators [S2] | Cancer patients | Ongoing | Treatment-based tariffs | — |
| Diagnostic imaging | 8 in-hospital imaging sites and 3 outpatient facilities (MRI, CT, X-ray); 2 imaging sites acquired in FY2025. Imaging volumes +9.0% in FY2025 and +4.2% in H1-2026 [S2][S3] | Referring doctors; inpatients and outpatients | Built through acquisitions (2022–2025) | Non-clinical facility fees. Radiologists' professional fees are separate under South African practice structures | East Coast Radiology (KZN, 2022); Eugene Marais Radiology (2022) [S13][S31] |
| Nuclear medicine / PET-CT | 3 PET-CT sites (Gauteng; acquired with TheraMed Nuclear in 2023), using PET-CT and SPECT-CT [S2][S31] | Oncology and cardiology referrals | 3 more PET-CT sites opening during FY2026 [S4] | Scan-based tariffs | — |
| Radiopharmaceutical manufacturing | 2 cyclotrons built in partnership with Axim to produce radiotracers locally [S2][S3] | Life's own PET-CT network and third parties | Awaiting final regulatory sign-off; commercial production expected after approval [S4] | Product supply pricing not disclosed | Gauteng cyclotrons (Axim joint venture) |
Healthcare services segment
| Offering | Description and capabilities | Target customer | Year / status | Pricing model | Notes |
|---|---|---|---|---|---|
| Life Nkanyisa | 7 facilities, 2 531 beds, 4 provinces [S2]. Long-term chronic care under contract to provincial governments | Provincial departments of health | Lost three contracts in FY2024; revenue pressure continuing [S9][S1] | Government contract per-bed / per-day rates | Credit-loss provision reversal in H1-2025 flattered the prior period [S3] |
| Life Health Solutions | Occupational health, wellness, emergency medical services and primary care: 198 on-site clinics, 12 off-site clinics, 14 mobile units, 8 EMS sites [S2] | Mining and industrial employers | Lost significant contracts; impairments of R63m (FY2025) and R29m (H1-2026) [S3] | Corporate service contracts | — |
| MyLife Clinic (primary care) | Low-cost primary care consultation offering, reportedly at R300 including basic medication [S29] | Uninsured / cash-paying patients | — | Flat fee | Source is a third-party commentary |
Cross-cutting and other
| Offering | Description | Status |
|---|---|---|
| Value-based care / integrated care products (ICPs) | Alternative reimbursement contracts with funders. Renal ICP reported "excellent outcomes" in FY2025 [S2] | Ongoing |
| Funder / network channel | Designated-service-provider (DSP) arrangements; 35% of PPDs in FY2025 [S2] | Ongoing |
| Learning centres (nursing education) | 7 learning centres; R76.8m invested in nurse training in FY2025 [S2][S26] | Ongoing |
| Specialist training programme | 9-year programme to train 40 surgical specialists, 35 medical specialists and 40 sub-specialists. Total investment R450m; management targets a 22% return over the period [S2] | Initiated FY2025 |
| LMI African rights | Retained right to manufacture, commercialise and distribute LMI products (e.g. NeuraCeq) in Africa [S2][S3] | Not yet monetised (nil revenue FY2025 and H1-2026) |
Financial Narrative
Southern Africa comparable operations (the continuing business)
Sources and derivations:
-
FY2022–FY2023 [S10]; FY2024–FY2025 [S2].
-
FY2021 is derived from aggregator segment data [S8] (hospitals and complementary R17.57bn plus healthcare services R1.46bn; EBITDA aggregated including corporate). It is approximate.
Growth summary:
-
Revenue CAGR FY2021–FY2025 (derived): c. 7.2% per year. FY2022–FY2025 CAGR: c. 7.9%.
-
Normalised EBITDA CAGR FY2021–FY2025 (derived): c. 4.3% per year.
-
The gap between revenue and EBITDA growth reflects margin erosion of c. 180 basis points.
Revenue growth (Southern Africa):
FY2022 revenue growth is derived. FY2023–FY2025 growth rates are company-reported (FY2024 EBITDA reported as −0.9% on the company basis) [S9][S10][S1].
Group as published and IFRS view (not like-for-like)
How to read this table:
Revenue as published: [S11][S10][S9][S1]:
-
FY2021–FY2022 include AMG and LMI.
-
FY2023 excludes AMG.
-
FY2024 includes LMI.
-
FY2025 excludes LMI.
Normalised EBITDA as published: FY2021–FY2022 are on a continuing basis including AMG [S11]. FY2023 is company-reported [S10]. FY2024 is derived from the company's reported +19.9% growth on FY2023, which included the LMI RM2 sublicence gain [S9]. FY2025 is from [S2].
- Gross profit, reported EBITDA, EBIT, pre-tax profit, net income, diluted EPS and margins: aggregator [S7]. The aggregator restates FY2022 onward to continuing operations, so FY2021 is not on the same basis.
Basic EPS: FY2021–FY2022 aggregator [S7]; FY2023–FY2025 company [S9][S1].
Dividends: company [S1][S2][S9][S10][S11].
Earnings-quality metrics (company-reported):
-
FY2023 HEPS is derived from FY2024's reported +73.4% growth [S9].
-
FY2024 NEPS restated to exclude LMI was 91.1 cents, so FY2025 NEPS growth was +10.1% [S1].
-
FY2025 continuing HEPS was −93.9 cents reported, or 107.1 cents pro forma excluding the R2 881m Piramal fair-value loss (+14.7% versus restated FY2024 of 93.4 cents) [S1].
H1-2026 snapshot [S3]:
-
Revenue R12 422m (+2.4%); normalised EBITDA R1 957m (+5.2%, margin 15.8%).
-
Operating profit before non-trading items R1 290m (+8.4%).
-
Attributable profit R771m (versus a R2 220m loss in H1-2025); NEPS 53.1 cents (+8.4%); interim dividend 23 cents (+9.5%).
FY2025 income statement walk (company, ZAR m) [S2]:
-
Revenue 25 104 → normalised EBITDA 3 845 (15.3%) → EBITA 2 708 → amortisation (175) → operating profit before non-trading items 2 533.
-
Non-trading items: Piramal fair-value loss (2 881); other non-trading (160), including R211m impairments.
-
Below the line: net finance costs (122); associates 10 → loss before tax (620); tax (721); non-controlling interest (107) → attributable loss from continuing operations (1 448).
-
Pro forma excluding Piramal: attributable profit R1 433m (+1.3%).
Balance sheet
Source: aggregator [S7]. FY2024–FY2025 debt and cash reconcile to the company's figures [S2].
Two distortions to note:
FY2023: AMG's assets and liabilities were classified as held for sale, which inflates working capital (R24.4bn of other current assets) and removes AMG goodwill from the goodwill line.
FY2025 total assets: R25 690m in the financial statements versus R24 186m in the company presentation. The difference is the R1 504m contingent-consideration receivable, which the presentation nets off [S2][S3].
Net debt including the Piramal liability [S2][S3]:
-
At 30 Sep 2025, reported net debt was only R141m, because LMI proceeds had been withheld to pay Piramal.
-
Including the R2 631m Piramal liability then due, adjusted net debt was R2 772m (0.77x EBITDA).
-
At 31 Mar 2026, after paying US$148m (R2 490m) to Piramal, net debt was R3 683m (0.93x covenant basis). A residual Piramal liability of R772m remains (cap: US$200m in total, of which US$148m has been paid).
H1-2026 balance sheet [S3]:
-
Total assets R23 434m; cash R1 131m.
-
Interest-bearing borrowings R4 814m (R4 659m non-current, R155m current); equity R11 943m.
-
Contingent-consideration receivable R1 526m, comprising LMI earn-outs and milestones of R1 361m and the Fresenius clawback of R165m.
Cash flow
Source: aggregator [S7]. Life does not run open-market buyback programmes; share purchases relate to employee incentive schemes.
Company-defined cash flow (continuing operations) [S2]:
FY2024 cash conversion is derived. FY2025 is company-reported [S1].
H1-2026 cash flow [S3]:
-
Cash generated from operations fell 32.9% to R1 315m. Working-capital outflow was R633m, after a R466m inflow in H2-2025, and staff-scheme cash settlement was R152m.
-
Capex was R722m (R525m replacement, R197m growth).
-
R2 490m was paid to settle financial liabilities (Piramal).
-
New notes raised R1 500m; bank loans of R750m were repaid.
Ratios
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Southern Africa revenue (ZAR Mn) | 19,030 | 19,971 | 21,985 | 23,674 | 25,104 |
Southern Africa normalised EBITDA (ZAR Mn) | 3,255 | 3,478 | 3,707 | 3,671 | 3,845 |
Southern Africa normalised EBITDA margin (%) | 17.1 | 17.4 | 16.9 | 15.5 | 15.3 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Southern Africa revenue growth (%) | 4.9 | 10.1 | 7.7 | 6.0 |
Southern Africa normalised EBITDA growth (%) | 6.9 | 6.6 | -1.0 | 4.7 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Group revenue as published (ZAR Mn) | 26,885 | 28,206 | 22,641 | 25,519 | 25,104 |
Group normalised EBITDA as published (ZAR Mn) | 5,051 | 5,039 | 3,594 | 4,309 | 3,845 |
Gross profit (ZAR Mn) | 8,354 | 5,873 | 6,481 | 6,692 | 7,057 |
Reported EBITDA (ZAR Mn) | 4,425 | 3,082 | 3,369 | 3,338 | 3,543 |
Operating profit EBIT (ZAR Mn) | 2,901 | 2,319 | 2,489 | 2,412 | 2,528 |
Pre-tax profit continuing (ZAR Mn) | 2,409 | 2,191 | 1,911 | 2,170 | -620 |
Net income attributable total ops (ZAR Mn) | 1,754 | 1,531 | 264 | 4,827 | 3,864 |
Basic EPS total ops (ZAR cents) | 121 | 106 | 18.3 | 328.8 | 263.0 |
Diluted EPS total ops (ZAR cents) | 120 | 105 | 18 | 329 | 263 |
Ordinary dividend per share (ZAR cents) | 25 | 40 | 44 | 50 | 56 |
Special dividend per share (ZAR cents) | 0 | 0 | 0 | 670 | 235 |
Gross margin (%) | 30.87 | 28.30 | 28.31 | 27.95 | 27.79 |
Operating margin (%) | 10.72 | 11.18 | 10.87 | 10.07 | 9.95 |
Net margin (%) | 6.48 | 7.38 | 1.15 | 19.81 | 14.87 |
Per-Share Data
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
HEPS total operations (ZAR cents) | 88.2 | 152.9 | -112.1 |
NEPS continuing as published (ZAR cents) | 89.1 | 132.3 | 100.3 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (ZAR Mn) | 40,781 | 42,238 | 45,615 | 24,344 | 25,690 |
Cash and equivalents (ZAR Mn) | 2,672 | 2,802 | 846 | 2,462 | 3,810 |
Short-term debt incl current leases (ZAR Mn) | 2,145 | 1,561 | 2,179 | 1,027 | 187 |
Long-term debt incl leases (ZAR Mn) | 10,914 | 12,124 | 11,010 | 3,394 | 3,764 |
Total debt (ZAR Mn) | 13,059 | 13,685 | 13,189 | 4,421 | 3,951 |
Net debt (ZAR Mn) | 10,387 | 10,875 | 12,327 | 1,959 | 141 |
Total equity (ZAR Mn) | 19,171 | 19,860 | 21,289 | 13,514 | 12,142 |
Goodwill and intangibles (ZAR Mn) | 16,383 | 16,514 | 3,287 | 3,570 | 2,333 |
Working capital (ZAR Mn) | -473 | 135 | 18,216 | 2,265 | 1,419 |
Book value per share (ZAR) | 12.42 | 12.98 | 14.04 | 8.69 | 7.95 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (ZAR Mn) | 5,142 | 4,184 | 4,670 | 4,819 | 5,025 |
Capex outflow PPE (ZAR Mn) | 1,707 | 1,263 | 1,213 | 1,297 | 1,638 |
Free cash flow (ZAR Mn) | 3,435 | 2,921 | 3,457 | 3,522 | 3,387 |
Dividends paid (ZAR Mn) | 0 | 587 | 616 | 9,472 | 5,233 |
Treasury share purchases for schemes (ZAR Mn) | 31 | 302 | 121 | 285 | 407 |
Disposal proceeds (ZAR Mn) | 0 | 0 | 0 | 19,466 | 5,649 |
Cash Flow and Margin Analysis (%)
| Metric | FY2024 | FY2025 |
|---|---|---|
Cash generated from operations (ZAR Mn) | 3,713 | 4,598 |
Maintenance capex (ZAR Mn) | 1,166 | 1,360 |
Growth capex (ZAR Mn) | 200 | 447 |
Company-defined free cash flow (ZAR Mn) | 1,278 | 1,745 |
Ordinary dividends paid (ZAR Mn) | 668 | 758 |
Special dividends paid (ZAR Mn) | 8,804 | 4,475 |
Cash conversion (% of normalised EBITDA) | 101.1 | 119.6 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Return on equity (%) | 9.44 | 7.63 | 6.94 | 8.82 | -10.45 |
Return on assets (%) | 4.34 | 3.49 | 3.54 | 4.31 | 6.32 |
Return on invested capital (%) | 6.86 | 5.22 | 5.78 | 6.95 | 18.22 |
Current ratio (x) | 0.94 | 1.02 | 2.63 | 1.43 | 1.20 |
Debt to equity (x) | 0.68 | 0.69 | 0.62 | 0.33 | 0.33 |
Net debt to EBITDA covenant basis (x) | 1.82 | 1.89 | 2.00 | 0.45 | 0.01 |
Interest coverage EBIT to interest (x) | 5.3 | 6.8 | 4.1 | 5.7 | 7.0 |
Asset turnover (x) | 0.65 | 0.50 | 0.52 | 0.69 | 1.01 |
Returns & Leverage Ratios (%)
| Metric | FY2024 | FY2025 | H1-2026 |
|---|---|---|---|
ROCE (%) | 20.0 | 17.8 | 17.8 |
Working Capital (Days)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Days sales outstanding (days) | 49.7 | 54.6 | 44.8 |
Days inventory outstanding (days) | 10.0 | 9.9 | 8.1 |
Days payables outstanding (days) | 38.8 | 40.9 | 39.7 |
Cash conversion cycle (days) | 20.9 | 23.6 | 13.2 |
Revenue by Region
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Southern Africa (ZAR Mn) | 19,030 | 19,971 | 21,985 | 23,674 | 25,104 |
International AMG UK and Europe (ZAR Mn) | 7,470 | 7,680 | 0 | 0 | 0 |
International LMI global radiopharma (ZAR Mn) | 385 | 555 | 656 | 1,845 | 0 |
Total as published (ZAR Mn) | 26,885 | 28,206 | 22,641 | 25,519 | 25,104 |
Region Margins & Growth (%)
| Region | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Southern Africa growth (%) | 4.9 | 10.1 | 7.7 |
LMI growth (%) | 44.2 | 18.2 | 181.3 |
Share Price and Market Valuation
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividend-adjusted FY-end share price (ZAR) | 10.01 | 7.72 | 9.28 | 11.66 | 10.99 |
Market capitalisation FY-end (ZAR Mn) | 33,131 | 25,086 | 29,250 | 23,043 | 16,714 |
Enterprise value FY-end (ZAR Mn) | 45,484 | 37,061 | 43,612 | 18,014 | 21,181 |
P/E (x) | 18.89 | 16.39 | 110.80 | 4.86 | 4.43 |
EV/EBITDA (x) | 10.28 | 12.03 | 12.95 | 5.40 | 5.98 |
EV/Sales (x) | 1.68 | 1.79 | 1.91 | 0.75 | 0.83 |
P/B (x) | 1.73 | 1.26 | 1.37 | 1.71 | 1.38 |
Dividend yield (%) | 2.50 | 5.18 | 4.74 | 4.29 | 5.10 |
Share Price & Returns
| Horizon | Return | Start date |
|---|---|---|
1-year | +10.8% | 30 Sep 2025 |
3-year | +31.3% | 29 Sep 2023 |
5-year | +21.7% | 30 Sep 2021 |
Valuation Snapshot
| Multiple | Value |
|---|---|
Trailing P/E | 12.98x (basis not fully disclosed) |
Forward P/E | 9.52x |
EV/EBITDA | 5.67x |
EV/Sales | 0.85x |
P/B | 1.46x |
Dividend yield | 5.75% |
Source Details
| Source | Consensus | Date |
|---|---|---|
TradersUnion aggregation | 12-month average target ZAC 1 264 (high 1 330; low 1 160) | As of 29 Sep 2026 |
Simply Wall St | Consensus fair value c. R12.86 (range R12.30–R13.70); references a JPMorgan upgrade | — |
MarketBeat (ADR) | Consensus "Hold" | — |
Per-Share Data and Capital Markets Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Interim dividend (ZAR cents) | 0 | 15 | 17 | 19 | 21 |
Final dividend (ZAR cents) | 25 | 25 | 27 | 31 | 35 |
Special dividends (ZAR cents) | 0 | 0 | 0 | 670 | 235 |
Total distributions (ZAR Mn) | 363 | 579 | 634 | 10,565 | 4,270 |
Capital Markets
| Item | Detail |
|---|---|
Rating | National scale zaAAA (improved in FY2025). Agency, outlook and global-scale ratings (Moody's / S&P / Fitch) not publicly disclosed in sources reviewed |
Covenant | Net debt to normalised EBITDA ceiling of 3.5x |
Undrawn facilities | R1.8bn (Sep 2025 and Mar 2026) |
Capital Instruments
| Instrument | FY2026 | FY2027 | FY2028 | FY2029 plus |
|---|---|---|---|---|
Bank debt and notes (ZAR Mn) | 20 | 1,975 | 500 | 775 |
Lease liabilities (ZAR Mn) | 167 | 105 | 91 | 318 |
Total debt (ZAR Mn) | 187 | 2,080 | 591 | 1,093 |
Analyst Conclusions
Management guidance for FY2026 (as revised 28 May 2026) [S4]:
-
Revenue growth of c. 2%.
-
PPDs relatively flat; occupancy c. 68%.
-
c. 140 specialists recruited.
-
Capex of c. R2.4bn.
-
Continued EBITDA margin improvement within a R400m, three-year savings programme.
-
Capacity additions: 87 acute beds, 64 rehab beds, a cathlab, a vascular lab and three PET-CT sites.
-
Cyclotron commercial production after regulatory approval.
-
Life Paarl Valley Hospital opening in FY2027.
Implied consensus growth (indicative):
-
Aggregator data suggest a forward P/E of c. 9.5x [S7].
-
One aggregator projects revenue growth of c.
-
Detailed sell-side consensus for EPS and EBITDA is not publicly disclosed in sources reviewed.
Bull case:
-
Operating leverage on recovery. Q2-2026 acute occupancy exceeded 70% even as H1 averaged 67.0% [S3]. If funder disruption fades and occupancy returns to c. 70%, the high-margin top-30 hospitals (96% of acute EBITDA) should drive margin expansion beyond the +50 basis points already delivered in H1-2026.
-
Self-help plus mix. R400m of savings (c. 10% of FY2025 EBITDA) [S2], combined with complementary services that are again growing at double digits with recovering margins (19.0%) [S3], could close part of the c. 300 basis point margin gap to Netcare.
-
Hidden optionality and valuation support. LMI earn-outs and RM2 milestones (up to US$400m plus up to €362.5m) are carried at only R1.4bn [S3]. The stock trades at c. 5.7x EV/EBITDA [S7], below the 6.3x LTM multiple implied for Mediclinic Southern Africa [S22], with a c. 5–6% dividend yield and low leverage.
Bear case:
-
Structural volume stagnation. Insured lives are flat (9.17 million) [S25]. Funder stress, as with Sizwe Hosmed, and lower tariffs (3.3%) [S3] can quickly erase guidance, as the May 2026 cut showed.
-
Margin structurally inferior. Margin fell from c. 17% to c. 15% over FY2021–FY2025 despite revenue growth. Renal integration issues, an optimisation-facility tail and Life Health Solutions impairments suggest execution risk [S2][S3].
-
Regulatory and competitive overhang, with less diversification. NHI litigation remains unresolved [S23]. A Remgro-backed Mediclinic Southern Africa is now a focused competitor [S22]. With all revenue in rand, there is no offshore earnings hedge [S3].
Concluding analyst verdict.
Life Healthcare enters FY2027 as a fundamentally different company from the one that listed in 2010. Three years of disciplined disposals turned an over-extended international portfolio into a lean, lowly geared, Southern African hospital and complementary-services franchise. Shareholders received roughly R13 billion in special dividends along the way.
What is clear: The strategic logic is sound — sell assets at full value, return the cash, and refocus capital on domestic capacity where demand is visible (ICU, mental health, renal, oncology, nuclear imaging). The balance sheet (0.93x net debt to EBITDA, zaAAA national rating) gives management ample room to fund Life Paarl Valley, buy back leased properties and pursue bolt-ons without straining dividends.
What remains unproven: whether the remaining business can earn returns that justify a re-rating. Normalised EBITDA margin has slipped from c. 17% to c. 15%, against Netcare's c. 18.6%. The FY2026 guidance cut showed how exposed the model is to funder disruption and tariff settlements. The Fresenius renal acquisition has proved harder to integrate than planned. Healthcare services is shrinking.
Where the swing factors lie: Near-term upside depends on two levers management controls (cost savings and asset optimisation) and one it does not (occupancy recovery).
Valuation: At c. 5.7x EV/EBITDA and a c. 5–6% dividend yield, the market prices Life as an ex-growth utility with regulatory risk. That is undemanding relative to the c. 6.3x private-market benchmark Remgro paid for Mediclinic Southern Africa, and it ascribes little value to LMI earn-outs that could be worth multiples of their R1.4 billion carrying value.
Verdict: a value-and-yield holding with credible self-help upside, but with limited structural growth. Evidence that margins are sustainably moving back above 16%, and a benign NHI ruling, are the two conditions most likely to unlock a re-rating. Until then, risk-reward appears balanced to modestly positive, consistent with the prevailing "Hold" consensus.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Education | Age | Remuneration |
|---|---|---|---|---|---|---|
Peter (Pete) Wharton-Hood | Group Chief Executive; executive director | Since 1 Sep 2020 | Standard Bank (joined 1997; Group COO and Deputy CEO); Deutsche Bank (CEO and Chief Country Officer South Africa from 2013; head of operations for the global markets division; global COO of corporate and investment banking) [S19][S28] | BCom, University of the Witwatersrand (1989); CA(SA); Harvard Advanced Management Programme [S19][S28] | Born 1965 (c. 61) [S19] | Single-figure remuneration of R55.107m per the latest remuneration report (reported May 2026) [S19]. Bought 220 299 LHC shares on 1 Jul 2025 (c. R3.1m) [S27] |
Pieter van der Westhuizen | Chief Financial Officer; executive director. Also responsible for IT and cyber since Apr 2024 | With the group for more than 25 years; CFO since c. 2015; acting CEO Jan–Aug 2020 and previously on an earlier occasion [S28][S32] | Life Healthcare finance roles | CA(SA) [S3] | — | Sold 53 544 shares on 15 Jan 2025 [S27] |
Adam Pyle | Chief Strategy and Growth Officer (from Apr 2024); formerly Chief Executive Southern Africa (more than 6 years) | 23 years with the group; retired 1 Jun 2026; advisory role for 7 months covering strategy, stakeholder relations and M&A [S16][S32] | — | — | — | — |
Joshila Ranchhod | Company Secretary | Current | — | — | — | — |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change |
|---|---|
Apr 2024 | Life and AMG executive committees combined after the AMG sale. Pyle moves from CEO Southern Africa to Chief Strategy and Growth Officer; CFO takes on IT and cyber |
5 Feb 2026 | Pyle's early retirement announced, effective 1 Jun 2026; he steps down from the Group Executive Committee |
1 Jun 2026 | Brett Mill appointed to the board of Life Healthcare Funding, replacing Pyle |
Aug 2022 | Lars Holmqvist and Dr Jeanne Bolger appointed |
Aug 2024 | Dr Fareed Abdullah and Dr Raymond Campbell appointed; Joel Netshitenzhe and Lars Holmqvist to retire at the 2025 AGM |
Feb 2025 | Netshitenzhe and Holmqvist retire |
7 Aug 2025 | Announced that Prof Marian Jacobs and Dr Jeanne Bolger will retire at the 2026 AGM; Board Charter and Nominations and Governance Committee terms updated |
19 Feb 2026 | Jacobs (Chair, Clinical Committee) and Bolger retire; Abdullah becomes Clinical Committee Chair |
Board of Directors
| Name | Role | Appointed / notes |
|---|---|---|
Dr Victor Litlhakanyane | Independent non-executive Chairman | Chair-designate from Jul 2020. MBChB (University of KwaZulu-Natal, 1988); MBA (University of the Free State); MD of Bigen Africa Health |
Peter Wharton-Hood | Chief Executive | 2020 |
Pieter van der Westhuizen | Chief Financial Officer | — |
Dr Fareed Abdullah | Independent non-executive director; Chairman of the Clinical Committee from Feb 2026 | Appointed Aug 2024 (South African Medical Research Council background) |
Dr Raymond Campbell | Independent non-executive director | Appointed Aug 2024 |
Caroline Henry | Independent non-executive director; member of the Social, Ethics and Transformation Committee | — |
Paul Moeketsi (TP Moeketsi) | Independent non-executive director | Appointed Feb 2023 |
Audrey Mothupi-Palmstierna | Independent non-executive director; member of the Social, Ethics and Transformation Committee | — |
Adv Mahlape Sello | Independent non-executive director; Chair of the Social, Ethics and Transformation Committee | — |
Fulvio Tonelli | Independent non-executive director | Appointed Apr 2023. Also a director of Absa Group and Equites Property Fund, and chair of the Independent Regulatory Board for Auditors. |
Major Shareholders
| Rank | Holder |
|---|---|
| 1 | Public Investment Corporation (incl. Government Employees Pension Fund mandates) |
| 2 | Sanlam Investment Management |
| 3 | Industrial Development Corporation of South Africa |
| 4 | Old Mutual Investment Group South Africa |
| 5 | Investment Solutions |
| 6 | Norges Bank Investment Management |
| 7 | Investec Wealth and Investment Management |
| 8 | Lazard Asset Management (increased stake, Mar 2026) |
Competitive Landscape
Competitors by Segment
| Segment | Competitors |
|---|---|
Acute hospitals | Netcare; Mediclinic Southern Africa (Remgro); Lenmed; National Hospital Network (NHN) affiliates; Busamed; Clinix; Joint Medical Holdings (JMH); Melomed |
Mental health | Netcare Akeso; Mediclinic mental health facilities |
Day surgery | Mediclinic day clinics; independent day-hospital groups (e.g. |
Primary / occupational care | Netcare Primary Care; Mediclinic's Intercare; ER24 (EMS) |
Diagnostic imaging | Independent radiology practices |
Peer Comparison FY2029
| Company | Latest revenue | Growth | EBITDA margin | Footprint | Positioning | Source |
|---|---|---|---|---|---|---|
Life Healthcare | R25.1bn (FY Sep 2025) | +6.0% | 15.3% | 42 acute hospitals, 8 085 acute beds; 74 renal sites | Diversified pure-play Southern Africa; lowest margin of the big three | [S1][S2] |
Netcare | R26.3bn (FY Sep 2025) | +4.5% | 18.6% | Largest by revenue; acute occupancy c. 65.0% | Margin and digitisation leader; share buybacks (10.4% of shares since Sep 2023) | [S21] |
Mediclinic Southern Africa | — | Southern Africa revenue +8% in the six months to Sep 2025 | Not disclosed (Mediclinic Holdings group adjusted margin 15.7%, including Switzerland) | c. 50 hospitals, 15 day clinics, 6 sub-acute, 6 mental health; 3 hospitals in Namibia | Now 100% Remgro-owned (US$947m; LTM EV/EBITDA c. 6.3x) | [S22] |
Lenmed | — | — | — | Hospitals in Gauteng, KwaZulu-Natal, Northern Cape, Eastern Cape | Independent group | [S24] |
NHN network | — | — | — | Network of independent hospitals | Collective contracting | [S24] |
Busamed | — | — | — | — | Independent | [S24] |
Clinix | — | — | — | Township-focused hospitals | Affordable segment | [S24] |
JMH | — | — | — | Durban | Independent | [S24] |
Netcare Akeso | Within Netcare | — | — | Mental health | Mental health competitor | [S21] |
Melomed | — | — | — | Western Cape | Relevant to Paarl expansion | General knowledge |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | Life Healthcare FY2025 | Netcare FY2025 | Mediclinic Holdings FY Mar 2026 |
|---|---|---|---|
Revenue | R25.1bn | R26.3bn | US$5.36bn (adjusted; includes Switzerland) |
Revenue growth | 6.0% | 4.5% | 11% |
Normalised EBITDA margin | 15.3% | 18.6% | 15.7% |
Most recent half-year revenue growth | 2.4% (H1-2026) | 4.8% (H1-2026) | — |
Most recent half-year EBITDA margin | 15.8% | 18.8% | — |
R&D intensity | Not disclosed / not applicable | Not disclosed / not applicable | Not disclosed / not applicable |
Net debt to EBITDA | 0.77x adjusted (0.93x at Mar 2026) | 1.1x | — |
“—” = not publicly disclosed.



